1076228-22-2

Upstream product

• 1076230-22-2 (3S,4S)-3-(4-fluoro-2-methylphenyl)piperidine-4-carboxylic acid [(S)-1-(3,5-bistrifluoromethylphenyl)ethyl]methylamide hydrochloride 
• 4595-61-3 pyrimidine-5-carboxylic acid 
• 471-47-6 oxamic acid 
• 40175-06-2 ethyl 1-methyl-1,2,5,6-tetrahydropyridine-4-carboxylate 
• 30897-90-6 (2-methyl-4-fluorophenyl)magnesium bromide 
• 414910-08-0 (1S)-1-[3,5-bis(trifluoromethyl)phenyl]-N-methylethanamine hydrochloride 
• 1357586-70-9 (3S,4S)-1-(tert-butoxycarbonyl)-3-(4-fluoro-2-methylphenyl)piperidine-4-carboxylic acid (S)-1-phenylethylamine complex 

Relevant academic research and scientific papers

Novel 3-phenylpiperidine-4-carboxamides as highly potent and orally long-acting neurokinin-1 receptor antagonists with reduced CYP3A induction

The synthesis and biological evaluation of a series of novel 3-phenylpiperidine-4-carboxamide derivatives are described. These compounds are generated by hybridization of the substructures from two types of tachykinin NK1 receptor antagonists.

PIPERIDINE DERIVATIVE AND USE THEREOF

The present invention provides a novel piperidine derivative and a tachykinin receptor antagonist containing same, as well as a compound represented by the formula:wherein R1 is carbamoylmethyl, methylsulfonylethylcarbonyl and the like; R2 is methyl or cyclopropyl; R3 is a hydrogen atom or methyl; R4 is a chlorine atom or trifluoromethyl; R5 is a chlorine atom or trifluoromethyl; and a group represented by the formula:is a group represented by the formula:wherein R6 is a hydrogen atom, methyl, ethyl or isopropyl; R7 is a hydrogen atom, methyl or a chlorine atom; and R8 is a hydrogen atom, a fluorine atom, a chlorine atom or methyl; or 3-methylthiophen-2-yl, and a salt thereof.